Syntara Ltd (SNT) - Net Assets
Based on the latest financial reports, Syntara Ltd (SNT) has net assets worth AU$16.02 Million AUD (≈ $11.33 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$21.44 Million ≈ $15.17 Million USD) and total liabilities (AU$5.42 Million ≈ $3.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Syntara Ltd (SNT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$16.02 Million |
| % of Total Assets | 74.7% |
| Annual Growth Rate | -2.69% |
| 5-Year Change | 463.02% |
| 10-Year Change | -23.45% |
| Growth Volatility | 104.67 |
Syntara Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Syntara Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Syntara Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Syntara Ltd (2003–2025)
The table below shows the annual net assets of Syntara Ltd from 2003 to 2025. For live valuation and market cap data, see market value of Syntara Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$16.02 Million ≈ $11.33 Million |
+242.26% |
| 2024-06-30 | AU$4.68 Million ≈ $3.31 Million |
-51.04% |
| 2023-06-30 | AU$9.56 Million ≈ $6.76 Million |
-11.52% |
| 2022-06-30 | AU$10.80 Million ≈ $7.64 Million |
+279.75% |
| 2021-06-30 | AU$2.85 Million ≈ $2.01 Million |
+98.81% |
| 2020-06-30 | AU$1.43 Million ≈ $1.01 Million |
-90.34% |
| 2019-06-30 | AU$14.81 Million ≈ $10.48 Million |
+33.24% |
| 2018-06-30 | AU$11.12 Million ≈ $7.87 Million |
+215.76% |
| 2017-06-30 | AU$3.52 Million ≈ $2.49 Million |
-83.17% |
| 2016-06-30 | AU$20.93 Million ≈ $14.81 Million |
-42.39% |
| 2015-06-30 | AU$36.32 Million ≈ $25.70 Million |
+101.04% |
| 2014-06-30 | AU$18.07 Million ≈ $12.78 Million |
-73.39% |
| 2013-06-30 | AU$67.89 Million ≈ $48.04 Million |
-38.17% |
| 2012-06-30 | AU$109.80 Million ≈ $77.69 Million |
+55.02% |
| 2011-06-30 | AU$70.83 Million ≈ $50.12 Million |
-38.42% |
| 2010-06-30 | AU$115.02 Million ≈ $81.38 Million |
-16.47% |
| 2009-06-30 | AU$137.69 Million ≈ $97.43 Million |
+15.59% |
| 2008-06-30 | AU$119.12 Million ≈ $84.29 Million |
+55.59% |
| 2007-06-30 | AU$76.56 Million ≈ $54.17 Million |
-22.58% |
| 2006-06-30 | AU$98.89 Million ≈ $69.97 Million |
+178.02% |
| 2005-06-30 | AU$35.57 Million ≈ $25.17 Million |
+32.82% |
| 2004-06-30 | AU$26.78 Million ≈ $18.95 Million |
-8.26% |
| 2003-06-30 | AU$29.19 Million ≈ $20.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Syntara Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40209853200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$417.88 Million | 2608.83% |
| Other Comprehensive Income | AU$3.15 Million | 19.65% |
| Total Equity | AU$16.02 Million | 100.00% |
Syntara Ltd Competitors by Market Cap
The table below lists competitors of Syntara Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Curo Holdings Co. Ltd
KQ:051780
|
$31.21 Million |
|
Santierul Naval Orsova SA
RO:SNO
|
$31.21 Million |
|
Projektengagemang Sweden AB (publ)
ST:PENG-B
|
$31.21 Million |
|
EasyJet PLC
LSE:EZJ
|
$31.21 Million |
|
SWISS PROPERTIES INV.100
F:SR1
|
$31.19 Million |
|
Fridenson
TA:FRDN
|
$31.18 Million |
|
Hulamin
JSE:HLM
|
$31.15 Million |
|
Zanaga Iron Ore Company Limited
F:6ZA
|
$31.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syntara Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,680,000 to 16,018,000, a change of 11,338,000 (242.3%).
- Net loss of 7,919,000 reduced equity.
- Share repurchases of 1,350,000 reduced equity.
- Other comprehensive income increased equity by 3,148,000.
- Other factors increased equity by 17,459,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.92 Million | -49.44% |
| Share Repurchases | AU$1.35 Million | -8.43% |
| Other Comprehensive Income | AU$3.15 Million | +19.65% |
| Other Changes | AU$17.46 Million | +109.0% |
| Total Change | AU$- | 242.26% |
Book Value vs Market Value Analysis
This analysis compares Syntara Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.10x to 2.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-06-30 | AU$0.28 | AU$0.03 | x |
| 2004-06-30 | AU$0.28 | AU$0.03 | x |
| 2005-06-30 | AU$0.27 | AU$0.03 | x |
| 2006-06-30 | AU$0.59 | AU$0.03 | x |
| 2007-06-30 | AU$0.41 | AU$0.03 | x |
| 2008-06-30 | AU$0.60 | AU$0.03 | x |
| 2009-06-30 | AU$0.67 | AU$0.03 | x |
| 2010-06-30 | AU$0.50 | AU$0.03 | x |
| 2011-06-30 | AU$0.30 | AU$0.03 | x |
| 2012-06-30 | AU$0.40 | AU$0.03 | x |
| 2013-06-30 | AU$0.22 | AU$0.03 | x |
| 2014-06-30 | AU$0.06 | AU$0.03 | x |
| 2015-06-30 | AU$0.12 | AU$0.03 | x |
| 2016-06-30 | AU$0.07 | AU$0.03 | x |
| 2017-06-30 | AU$0.01 | AU$0.03 | x |
| 2018-06-30 | AU$0.03 | AU$0.03 | x |
| 2019-06-30 | AU$0.04 | AU$0.03 | x |
| 2020-06-30 | AU$0.00 | AU$0.03 | x |
| 2021-06-30 | AU$0.01 | AU$0.03 | x |
| 2022-06-30 | AU$0.02 | AU$0.03 | x |
| 2023-06-30 | AU$0.01 | AU$0.03 | x |
| 2024-06-30 | AU$0.00 | AU$0.03 | x |
| 2025-06-30 | AU$0.01 | AU$0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Syntara Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -105.87%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.34x
- Recent ROE (-49.44%) is above the historical average (-124.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -5.03% | -3541.88% | 0.00x | 1.02x | AU$-4.39 Million |
| 2004 | -22.41% | 0.00% | 0.00x | 1.06x | AU$-8.68 Million |
| 2005 | -28.77% | -2046471.40% | 0.00x | 1.07x | AU$-13.79 Million |
| 2006 | -17.93% | -221662.50% | 0.00x | 1.05x | AU$-27.62 Million |
| 2007 | -31.58% | -1025.84% | 0.03x | 1.08x | AU$-31.83 Million |
| 2008 | -17.16% | -3878.56% | 0.00x | 1.05x | AU$-32.35 Million |
| 2009 | -25.54% | -3431.32% | 0.01x | 1.19x | AU$-48.94 Million |
| 2010 | -40.29% | -3961.11% | 0.01x | 1.22x | AU$-57.85 Million |
| 2011 | -64.60% | -3806.82% | 0.01x | 1.34x | AU$-52.84 Million |
| 2012 | -35.19% | -2636.02% | 0.01x | 1.20x | AU$-49.62 Million |
| 2013 | -64.12% | -1344.98% | 0.03x | 1.65x | AU$-50.33 Million |
| 2014 | -286.81% | -1028.95% | 0.08x | 3.69x | AU$-53.62 Million |
| 2015 | 50.84% | 31.98% | 0.70x | 2.27x | AU$14.83 Million |
| 2016 | -78.67% | -114.84% | 0.22x | 3.14x | AU$-18.56 Million |
| 2017 | -521.05% | -138.09% | 0.29x | 12.90x | AU$-18.70 Million |
| 2018 | 57.82% | 88.27% | 0.15x | 4.51x | AU$5.32 Million |
| 2019 | -135.40% | -353.38% | 0.11x | 3.56x | AU$-21.54 Million |
| 2020 | -974.35% | -198.42% | 0.20x | 24.75x | AU$-14.09 Million |
| 2021 | -104.39% | -39.99% | 0.22x | 11.81x | AU$-3.25 Million |
| 2022 | -17.92% | -33.58% | 0.23x | 2.33x | AU$-3.02 Million |
| 2023 | -118.84% | -197.05% | 0.24x | 2.51x | AU$-12.32 Million |
| 2024 | -323.55% | -278.96% | 0.52x | 2.22x | AU$-15.61 Million |
| 2025 | -49.44% | -105.87% | 0.35x | 1.34x | AU$-9.52 Million |
Industry Comparison
This section compares Syntara Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $29,670,098
- Average return on equity (ROE) among peers: 4903.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syntara Ltd (SNT) | AU$16.02 Million | -5.03% | 0.34x | $31.20 Million |
| Althea Group Holdings Ltd (AGH) | $41.45 Million | -29.25% | 0.36x | $12.05 Million |
| BOD Science Ltd (BOD) | $3.47 Million | -155.95% | 0.53x | $3.01 Million |
| BPH Global Ltd (BP8) | $149.84K | 50079.24% | 22.90x | $2.62 Million |
| Cann Group Ltd (CAN) | $648.33K | -644.19% | 0.12x | $5.62 Million |
| ECS Botanics Holdings Ltd (ECS) | $319.74K | -109.87% | 0.16x | $5.65 Million |
| Ecofibre Ltd (EOF) | $109.94 Million | -13.34% | 0.36x | $5.36 Million |
| Epsilon Healthcare Ltd (EPN) | $2.99 Million | -68.61% | 4.98x | $5.51 Million |
| Elixinol Wellness Ltd (EXL) | $99.42 Million | 0.00% | 0.04x | $2.05 Million |
| IDT Australia Ltd (IDT) | $32.86 Million | 21.64% | 0.29x | $12.10 Million |
| Invion Ltd (IVX) | $5.46 Million | -46.66% | 0.11x | $3.70 Million |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more